nodes	percent_of_prediction	percent_of_DWPC	metapath
Rufinamide—CYP3A4—bone cancer	0.772	1	CbGaD
Rufinamide—GRM5—GPCRs, Class C Metabotropic glutamate, pheromone—GRM4—bone cancer	0.0174	0.121	CbGpPWpGaD
Rufinamide—GRM5—GPCRs, Class C Metabotropic glutamate, pheromone—GRM1—bone cancer	0.015	0.105	CbGpPWpGaD
Rufinamide—GRM5—Hypothetical Network for Drug Addiction—GRM1—bone cancer	0.00821	0.0574	CbGpPWpGaD
Rufinamide—GRM5—Class C/3 (Metabotropic glutamate/pheromone receptors)—GRM4—bone cancer	0.00792	0.0553	CbGpPWpGaD
Rufinamide—CYP2E1—Felbamate Metabolism—CYP3A4—bone cancer	0.00708	0.0495	CbGpPWpGaD
Rufinamide—GRM5—Class C/3 (Metabotropic glutamate/pheromone receptors)—GRM1—bone cancer	0.00687	0.048	CbGpPWpGaD
Rufinamide—CES1—Irinotecan Pathway—CYP3A4—bone cancer	0.00525	0.0367	CbGpPWpGaD
Rufinamide—SCN5A—Cardiac Progenitor Differentiation—T—bone cancer	0.00504	0.0352	CbGpPWpGaD
Rufinamide—CES1—Fluoropyrimidine Activity—DHFR—bone cancer	0.00312	0.0218	CbGpPWpGaD
Rufinamide—SCN5A—SIDS Susceptibility Pathways—FEV—bone cancer	0.0025	0.0175	CbGpPWpGaD
Rufinamide—CYP2E1—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00233	0.0162	CbGpPWpGaD
Rufinamide—GRM5—G alpha (q) signalling events—GRM1—bone cancer	0.002	0.014	CbGpPWpGaD
Rufinamide—GRM5—Gastrin-CREB signalling pathway via PKC and MAPK—GRM1—bone cancer	0.00179	0.0125	CbGpPWpGaD
Rufinamide—Infection—Carboplatin—bone cancer	0.00177	0.021	CcSEcCtD
Rufinamide—CES1—E2F transcription factor network—DHFR—bone cancer	0.00165	0.0116	CbGpPWpGaD
Rufinamide—ALB—Folate Metabolism—FOLR1—bone cancer	0.0016	0.0111	CbGpPWpGaD
Rufinamide—CYP2E1—Fatty Acid Omega Oxidation—CYP3A4—bone cancer	0.00134	0.00937	CbGpPWpGaD
Rufinamide—GRM5—G alpha (q) signalling events—GNA11—bone cancer	0.00129	0.009	CbGpPWpGaD
Rufinamide—CYP2E1—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.00126	0.00878	CbGpPWpGaD
Rufinamide—Polyuria—Cisplatin—bone cancer	0.00121	0.0144	CcSEcCtD
Rufinamide—GRM5—GPCR ligand binding—GRM4—bone cancer	0.00116	0.00813	CbGpPWpGaD
Rufinamide—GRM5—Gastrin-CREB signalling pathway via PKC and MAPK—GNA11—bone cancer	0.00115	0.00805	CbGpPWpGaD
Rufinamide—CYP2E1—Xenobiotics—CYP3A4—bone cancer	0.00112	0.00784	CbGpPWpGaD
Rufinamide—CYP2E1—Tamoxifen metabolism—CYP3A4—bone cancer	0.00108	0.00754	CbGpPWpGaD
Rufinamide—CYP3A4—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00108	0.00754	CbGpPWpGaD
Rufinamide—Nystagmus—Epirubicin—bone cancer	0.00106	0.0125	CcSEcCtD
Rufinamide—CYP3A4—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.00101	0.00709	CbGpPWpGaD
Rufinamide—GRM5—GPCR ligand binding—GRM1—bone cancer	0.00101	0.00705	CbGpPWpGaD
Rufinamide—CYP2E1—Metapathway biotransformation—CYP4V2—bone cancer	0.001	0.00699	CbGpPWpGaD
Rufinamide—Nystagmus—Doxorubicin—bone cancer	0.000976	0.0116	CcSEcCtD
Rufinamide—Breast disorder—Cisplatin—bone cancer	0.000963	0.0114	CcSEcCtD
Rufinamide—Nasopharyngitis—Cisplatin—bone cancer	0.000953	0.0113	CcSEcCtD
Rufinamide—CES1—E2F transcription factor network—PLAU—bone cancer	0.000919	0.00642	CbGpPWpGaD
Rufinamide—Bone disorder—Methotrexate—bone cancer	0.000892	0.0106	CcSEcCtD
Rufinamide—Bone disorder—Epirubicin—bone cancer	0.000834	0.00988	CcSEcCtD
Rufinamide—Nocturia—Epirubicin—bone cancer	0.000813	0.00962	CcSEcCtD
Rufinamide—Hepatobiliary disease—Cisplatin—bone cancer	0.000776	0.00919	CcSEcCtD
Rufinamide—Gait disturbance—Epirubicin—bone cancer	0.000772	0.00914	CcSEcCtD
Rufinamide—Bone disorder—Doxorubicin—bone cancer	0.000772	0.00914	CcSEcCtD
Rufinamide—Coordination abnormal—Epirubicin—bone cancer	0.000768	0.00908	CcSEcCtD
Rufinamide—CES1—E2F transcription factor network—RB1—bone cancer	0.000755	0.00528	CbGpPWpGaD
Rufinamide—Nocturia—Doxorubicin—bone cancer	0.000752	0.0089	CcSEcCtD
Rufinamide—CYP2E1—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000734	0.00513	CbGpPWpGaD
Rufinamide—Urine output increased—Methotrexate—bone cancer	0.000728	0.00862	CcSEcCtD
Rufinamide—Urinary tract disorder—Cisplatin—bone cancer	0.000728	0.00861	CcSEcCtD
Rufinamide—Urethral disorder—Cisplatin—bone cancer	0.000723	0.00855	CcSEcCtD
Rufinamide—Gait disturbance—Doxorubicin—bone cancer	0.000715	0.00846	CcSEcCtD
Rufinamide—GRM5—GPCR ligand binding—SMO—bone cancer	0.00071	0.00496	CbGpPWpGaD
Rufinamide—Coordination abnormal—Doxorubicin—bone cancer	0.00071	0.0084	CcSEcCtD
Rufinamide—CES1—Fluoropyrimidine Activity—TP53—bone cancer	0.000697	0.00487	CbGpPWpGaD
Rufinamide—Eye disorder—Cisplatin—bone cancer	0.000689	0.00815	CcSEcCtD
Rufinamide—CES1—NRF2 pathway—GSTP1—bone cancer	0.000688	0.00481	CbGpPWpGaD
Rufinamide—CES1—NRF2 pathway—TGFBR2—bone cancer	0.000688	0.00481	CbGpPWpGaD
Rufinamide—Lymphadenopathy—Methotrexate—bone cancer	0.000685	0.00811	CcSEcCtD
Rufinamide—SCN5A—Cardiac Progenitor Differentiation—KIT—bone cancer	0.000684	0.00478	CbGpPWpGaD
Rufinamide—Cardiac disorder—Cisplatin—bone cancer	0.000684	0.0081	CcSEcCtD
Rufinamide—Polyuria—Methotrexate—bone cancer	0.000666	0.00788	CcSEcCtD
Rufinamide—Immune system disorder—Cisplatin—bone cancer	0.000666	0.00788	CcSEcCtD
Rufinamide—Mediastinal disorder—Cisplatin—bone cancer	0.000664	0.00786	CcSEcCtD
Rufinamide—GRM5—GPCR downstream signaling—GRM4—bone cancer	0.000657	0.00459	CbGpPWpGaD
Rufinamide—GRM5—GPCR downstream signaling—RGS1—bone cancer	0.000657	0.00459	CbGpPWpGaD
Rufinamide—ALB—Binding and Uptake of Ligands by Scavenger Receptors—SPARC—bone cancer	0.000655	0.00458	CbGpPWpGaD
Rufinamide—Malnutrition—Cisplatin—bone cancer	0.000642	0.00759	CcSEcCtD
Rufinamide—Lymphadenopathy—Epirubicin—bone cancer	0.000641	0.00759	CcSEcCtD
Rufinamide—Vision blurred—Cisplatin—bone cancer	0.000605	0.00716	CcSEcCtD
Rufinamide—Tremor—Cisplatin—bone cancer	0.000601	0.00711	CcSEcCtD
Rufinamide—GRM5—Signaling by GPCR—RGS1—bone cancer	0.000597	0.00417	CbGpPWpGaD
Rufinamide—GRM5—Signaling by GPCR—GRM4—bone cancer	0.000597	0.00417	CbGpPWpGaD
Rufinamide—Lymphadenopathy—Doxorubicin—bone cancer	0.000593	0.00702	CcSEcCtD
Rufinamide—Anaemia—Cisplatin—bone cancer	0.000593	0.00702	CcSEcCtD
Rufinamide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000583	0.00407	CbGpPWpGaD
Rufinamide—Increased appetite—Epirubicin—bone cancer	0.000582	0.00689	CcSEcCtD
Rufinamide—CYP2E1—Tryptophan metabolism—CYP3A4—bone cancer	0.000576	0.00403	CbGpPWpGaD
Rufinamide—Leukopenia—Cisplatin—bone cancer	0.000574	0.0068	CcSEcCtD
Rufinamide—GRM5—GPCR downstream signaling—GRM1—bone cancer	0.00057	0.00398	CbGpPWpGaD
Rufinamide—SCN7A—L1CAM interactions—EGFR—bone cancer	0.000557	0.0039	CbGpPWpGaD
Rufinamide—Convulsion—Cisplatin—bone cancer	0.000556	0.00658	CcSEcCtD
Rufinamide—Ataxia—Methotrexate—bone cancer	0.00055	0.00651	CcSEcCtD
Rufinamide—Diplopia—Epirubicin—bone cancer	0.000547	0.00648	CcSEcCtD
Rufinamide—Anxiety—Cisplatin—bone cancer	0.000544	0.00644	CcSEcCtD
Rufinamide—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—bone cancer	0.000542	0.00642	CcSEcCtD
Rufinamide—Increased appetite—Doxorubicin—bone cancer	0.000539	0.00638	CcSEcCtD
Rufinamide—Breast disorder—Methotrexate—bone cancer	0.000528	0.00625	CcSEcCtD
Rufinamide—Infection—Cisplatin—bone cancer	0.00052	0.00616	CcSEcCtD
Rufinamide—GRM5—Signaling by GPCR—GRM1—bone cancer	0.000517	0.00362	CbGpPWpGaD
Rufinamide—Ataxia—Epirubicin—bone cancer	0.000514	0.00609	CcSEcCtD
Rufinamide—Nervous system disorder—Cisplatin—bone cancer	0.000514	0.00608	CcSEcCtD
Rufinamide—Thrombocytopenia—Cisplatin—bone cancer	0.000513	0.00607	CcSEcCtD
Rufinamide—Skin disorder—Cisplatin—bone cancer	0.000509	0.00602	CcSEcCtD
Rufinamide—Diplopia—Doxorubicin—bone cancer	0.000506	0.00599	CcSEcCtD
Rufinamide—Abdominal pain upper—Epirubicin—bone cancer	0.0005	0.00591	CcSEcCtD
Rufinamide—Anorexia—Cisplatin—bone cancer	0.000499	0.00591	CcSEcCtD
Rufinamide—SCN11A—L1CAM interactions—EGFR—bone cancer	0.000497	0.00347	CbGpPWpGaD
Rufinamide—Breast disorder—Epirubicin—bone cancer	0.000494	0.00585	CcSEcCtD
Rufinamide—Nasopharyngitis—Epirubicin—bone cancer	0.000489	0.00579	CcSEcCtD
Rufinamide—Ataxia—Doxorubicin—bone cancer	0.000476	0.00563	CcSEcCtD
Rufinamide—Influenza—Epirubicin—bone cancer	0.000473	0.0056	CcSEcCtD
Rufinamide—Dysuria—Methotrexate—bone cancer	0.000473	0.00559	CcSEcCtD
Rufinamide—Neutropenia—Methotrexate—bone cancer	0.000473	0.00559	CcSEcCtD
Rufinamide—CYP2E1—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000466	0.00326	CbGpPWpGaD
Rufinamide—CYP3A4—Metapathway biotransformation—CYP4V2—bone cancer	0.000464	0.00324	CbGpPWpGaD
Rufinamide—Abdominal pain upper—Doxorubicin—bone cancer	0.000462	0.00547	CcSEcCtD
Rufinamide—CYP2E1—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.00046	0.00321	CbGpPWpGaD
Rufinamide—Breast disorder—Doxorubicin—bone cancer	0.000457	0.00541	CcSEcCtD
Rufinamide—Decreased appetite—Cisplatin—bone cancer	0.000455	0.00539	CcSEcCtD
Rufinamide—Bronchitis—Epirubicin—bone cancer	0.000455	0.00538	CcSEcCtD
Rufinamide—SCN8A—L1CAM interactions—EGFR—bone cancer	0.000454	0.00318	CbGpPWpGaD
Rufinamide—Pneumonia—Methotrexate—bone cancer	0.000453	0.00536	CcSEcCtD
Rufinamide—Nasopharyngitis—Doxorubicin—bone cancer	0.000453	0.00536	CcSEcCtD
Rufinamide—Gastrointestinal disorder—Cisplatin—bone cancer	0.000452	0.00535	CcSEcCtD
Rufinamide—Infestation—Methotrexate—bone cancer	0.000451	0.00533	CcSEcCtD
Rufinamide—Infestation NOS—Methotrexate—bone cancer	0.000451	0.00533	CcSEcCtD
Rufinamide—Dysuria—Epirubicin—bone cancer	0.000442	0.00523	CcSEcCtD
Rufinamide—Neutropenia—Epirubicin—bone cancer	0.000442	0.00523	CcSEcCtD
Rufinamide—ALB—Folate Metabolism—DHFR—bone cancer	0.000438	0.00306	CbGpPWpGaD
Rufinamide—Influenza—Doxorubicin—bone cancer	0.000438	0.00518	CcSEcCtD
Rufinamide—Pollakiuria—Epirubicin—bone cancer	0.000437	0.00517	CcSEcCtD
Rufinamide—Haematuria—Methotrexate—bone cancer	0.00043	0.00508	CcSEcCtD
Rufinamide—Weight decreased—Epirubicin—bone cancer	0.000428	0.00506	CcSEcCtD
Rufinamide—Hepatobiliary disease—Methotrexate—bone cancer	0.000426	0.00504	CcSEcCtD
Rufinamide—Epistaxis—Methotrexate—bone cancer	0.000425	0.00503	CcSEcCtD
Rufinamide—Pneumonia—Epirubicin—bone cancer	0.000424	0.00502	CcSEcCtD
Rufinamide—Infestation NOS—Epirubicin—bone cancer	0.000422	0.00499	CcSEcCtD
Rufinamide—Infestation—Epirubicin—bone cancer	0.000422	0.00499	CcSEcCtD
Rufinamide—Bronchitis—Doxorubicin—bone cancer	0.000421	0.00498	CcSEcCtD
Rufinamide—SCN7A—Axon guidance—MET—bone cancer	0.000416	0.00291	CbGpPWpGaD
Rufinamide—Dysuria—Doxorubicin—bone cancer	0.000409	0.00484	CcSEcCtD
Rufinamide—Neutropenia—Doxorubicin—bone cancer	0.000409	0.00484	CcSEcCtD
Rufinamide—Pollakiuria—Doxorubicin—bone cancer	0.000404	0.00478	CcSEcCtD
Rufinamide—Haematuria—Epirubicin—bone cancer	0.000402	0.00476	CcSEcCtD
Rufinamide—Urinary tract disorder—Methotrexate—bone cancer	0.000399	0.00473	CcSEcCtD
Rufinamide—Hepatobiliary disease—Epirubicin—bone cancer	0.000399	0.00472	CcSEcCtD
Rufinamide—Epistaxis—Epirubicin—bone cancer	0.000398	0.00471	CcSEcCtD
Rufinamide—Urethral disorder—Methotrexate—bone cancer	0.000396	0.00469	CcSEcCtD
Rufinamide—Weight decreased—Doxorubicin—bone cancer	0.000396	0.00468	CcSEcCtD
Rufinamide—Sinusitis—Epirubicin—bone cancer	0.000396	0.00468	CcSEcCtD
Rufinamide—Pneumonia—Doxorubicin—bone cancer	0.000392	0.00464	CcSEcCtD
Rufinamide—Infestation NOS—Doxorubicin—bone cancer	0.00039	0.00462	CcSEcCtD
Rufinamide—Infestation—Doxorubicin—bone cancer	0.00039	0.00462	CcSEcCtD
Rufinamide—Hypersensitivity—Cisplatin—bone cancer	0.000386	0.00457	CcSEcCtD
Rufinamide—ALB—Platelet degranulation—SPARC—bone cancer	0.000384	0.00268	CbGpPWpGaD
Rufinamide—Rhinitis—Epirubicin—bone cancer	0.000379	0.00449	CcSEcCtD
Rufinamide—Eye disorder—Methotrexate—bone cancer	0.000378	0.00447	CcSEcCtD
Rufinamide—CYP2E1—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000378	0.00264	CbGpPWpGaD
Rufinamide—Asthenia—Cisplatin—bone cancer	0.000376	0.00445	CcSEcCtD
Rufinamide—Cardiac disorder—Methotrexate—bone cancer	0.000375	0.00444	CcSEcCtD
Rufinamide—Urinary tract disorder—Epirubicin—bone cancer	0.000374	0.00442	CcSEcCtD
Rufinamide—Haematuria—Doxorubicin—bone cancer	0.000372	0.0044	CcSEcCtD
Rufinamide—Urethral disorder—Epirubicin—bone cancer	0.000371	0.00439	CcSEcCtD
Rufinamide—SCN11A—Axon guidance—MET—bone cancer	0.000371	0.00259	CbGpPWpGaD
Rufinamide—Hepatobiliary disease—Doxorubicin—bone cancer	0.000369	0.00437	CcSEcCtD
Rufinamide—Epistaxis—Doxorubicin—bone cancer	0.000368	0.00435	CcSEcCtD
Rufinamide—SCN9A—L1CAM interactions—EGFR—bone cancer	0.000368	0.00257	CbGpPWpGaD
Rufinamide—GRM5—GPCR downstream signaling—GNA11—bone cancer	0.000367	0.00257	CbGpPWpGaD
Rufinamide—Sinusitis—Doxorubicin—bone cancer	0.000366	0.00433	CcSEcCtD
Rufinamide—ALB—Response to elevated platelet cytosolic Ca2+—SPARC—bone cancer	0.000365	0.00255	CbGpPWpGaD
Rufinamide—Immune system disorder—Methotrexate—bone cancer	0.000365	0.00432	CcSEcCtD
Rufinamide—GRM5—Signaling by GPCR—SMO—bone cancer	0.000365	0.00255	CbGpPWpGaD
Rufinamide—Mediastinal disorder—Methotrexate—bone cancer	0.000365	0.00431	CcSEcCtD
Rufinamide—Diarrhoea—Cisplatin—bone cancer	0.000358	0.00424	CcSEcCtD
Rufinamide—Mental disorder—Methotrexate—bone cancer	0.000354	0.00419	CcSEcCtD
Rufinamide—Eye disorder—Epirubicin—bone cancer	0.000354	0.00419	CcSEcCtD
Rufinamide—GRM5—Signaling Pathways—GRM4—bone cancer	0.000353	0.00246	CbGpPWpGaD
Rufinamide—GRM5—Signaling Pathways—RGS1—bone cancer	0.000353	0.00246	CbGpPWpGaD
Rufinamide—Malnutrition—Methotrexate—bone cancer	0.000352	0.00417	CcSEcCtD
Rufinamide—SCN3A—L1CAM interactions—EGFR—bone cancer	0.000352	0.00246	CbGpPWpGaD
Rufinamide—Cardiac disorder—Epirubicin—bone cancer	0.000351	0.00416	CcSEcCtD
Rufinamide—Rhinitis—Doxorubicin—bone cancer	0.000351	0.00416	CcSEcCtD
Rufinamide—SCN7A—Axon guidance—MMP2—bone cancer	0.000347	0.00242	CbGpPWpGaD
Rufinamide—Urinary tract disorder—Doxorubicin—bone cancer	0.000346	0.00409	CcSEcCtD
Rufinamide—Urethral disorder—Doxorubicin—bone cancer	0.000343	0.00406	CcSEcCtD
Rufinamide—Immune system disorder—Epirubicin—bone cancer	0.000342	0.00405	CcSEcCtD
Rufinamide—Mediastinal disorder—Epirubicin—bone cancer	0.000341	0.00404	CcSEcCtD
Rufinamide—Back pain—Methotrexate—bone cancer	0.000341	0.00403	CcSEcCtD
Rufinamide—SCN8A—Axon guidance—MET—bone cancer	0.000339	0.00237	CbGpPWpGaD
Rufinamide—SCN4A—L1CAM interactions—EGFR—bone cancer	0.000338	0.00236	CbGpPWpGaD
Rufinamide—SCN2A—L1CAM interactions—EGFR—bone cancer	0.000338	0.00236	CbGpPWpGaD
Rufinamide—GRM5—Signaling by GPCR—GNA11—bone cancer	0.000333	0.00233	CbGpPWpGaD
Rufinamide—Vomiting—Cisplatin—bone cancer	0.000333	0.00394	CcSEcCtD
Rufinamide—GRM5—GPCR downstream signaling—IL3—bone cancer	0.000333	0.00233	CbGpPWpGaD
Rufinamide—Vision blurred—Methotrexate—bone cancer	0.000332	0.00393	CcSEcCtD
Rufinamide—Mental disorder—Epirubicin—bone cancer	0.000332	0.00392	CcSEcCtD
Rufinamide—Rash—Cisplatin—bone cancer	0.00033	0.00391	CcSEcCtD
Rufinamide—Dermatitis—Cisplatin—bone cancer	0.00033	0.0039	CcSEcCtD
Rufinamide—Malnutrition—Epirubicin—bone cancer	0.000329	0.0039	CcSEcCtD
Rufinamide—GRM5—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—bone cancer	0.000328	0.00229	CbGpPWpGaD
Rufinamide—Eye disorder—Doxorubicin—bone cancer	0.000327	0.00387	CcSEcCtD
Rufinamide—SCN1A—L1CAM interactions—EGFR—bone cancer	0.000326	0.00228	CbGpPWpGaD
Rufinamide—SCN10A—L1CAM interactions—EGFR—bone cancer	0.000326	0.00228	CbGpPWpGaD
Rufinamide—Anaemia—Methotrexate—bone cancer	0.000325	0.00385	CcSEcCtD
Rufinamide—Cardiac disorder—Doxorubicin—bone cancer	0.000325	0.00385	CcSEcCtD
Rufinamide—Back pain—Epirubicin—bone cancer	0.000319	0.00377	CcSEcCtD
Rufinamide—Immune system disorder—Doxorubicin—bone cancer	0.000316	0.00374	CcSEcCtD
Rufinamide—Vertigo—Methotrexate—bone cancer	0.000316	0.00374	CcSEcCtD
Rufinamide—Mediastinal disorder—Doxorubicin—bone cancer	0.000316	0.00374	CcSEcCtD
Rufinamide—Leukopenia—Methotrexate—bone cancer	0.000315	0.00373	CcSEcCtD
Rufinamide—Nausea—Cisplatin—bone cancer	0.000311	0.00368	CcSEcCtD
Rufinamide—Vision blurred—Epirubicin—bone cancer	0.000311	0.00367	CcSEcCtD
Rufinamide—SCN11A—Axon guidance—MMP2—bone cancer	0.000309	0.00216	CbGpPWpGaD
Rufinamide—Mental disorder—Doxorubicin—bone cancer	0.000307	0.00363	CcSEcCtD
Rufinamide—GRM5—Signaling Pathways—GRM1—bone cancer	0.000306	0.00214	CbGpPWpGaD
Rufinamide—Convulsion—Methotrexate—bone cancer	0.000305	0.00361	CcSEcCtD
Rufinamide—Malnutrition—Doxorubicin—bone cancer	0.000305	0.00361	CcSEcCtD
Rufinamide—Anaemia—Epirubicin—bone cancer	0.000305	0.0036	CcSEcCtD
Rufinamide—Agitation—Epirubicin—bone cancer	0.000303	0.00358	CcSEcCtD
Rufinamide—GRM5—Signaling by GPCR—IL3—bone cancer	0.000302	0.00211	CbGpPWpGaD
Rufinamide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	0.000298	0.00352	CcSEcCtD
Rufinamide—SCN7A—Developmental Biology—MET—bone cancer	0.000297	0.00207	CbGpPWpGaD
Rufinamide—SCN7A—Developmental Biology—CDK4—bone cancer	0.000297	0.00207	CbGpPWpGaD
Rufinamide—Vertigo—Epirubicin—bone cancer	0.000296	0.0035	CcSEcCtD
Rufinamide—Leukopenia—Epirubicin—bone cancer	0.000295	0.00349	CcSEcCtD
Rufinamide—Back pain—Doxorubicin—bone cancer	0.000295	0.00349	CcSEcCtD
Rufinamide—Vision blurred—Doxorubicin—bone cancer	0.000287	0.0034	CcSEcCtD
Rufinamide—Convulsion—Epirubicin—bone cancer	0.000285	0.00338	CcSEcCtD
Rufinamide—Infection—Methotrexate—bone cancer	0.000285	0.00338	CcSEcCtD
Rufinamide—SCN8A—Axon guidance—MMP2—bone cancer	0.000283	0.00198	CbGpPWpGaD
Rufinamide—Nervous system disorder—Methotrexate—bone cancer	0.000282	0.00333	CcSEcCtD
Rufinamide—Anaemia—Doxorubicin—bone cancer	0.000282	0.00333	CcSEcCtD
Rufinamide—Thrombocytopenia—Methotrexate—bone cancer	0.000281	0.00333	CcSEcCtD
Rufinamide—Agitation—Doxorubicin—bone cancer	0.00028	0.00332	CcSEcCtD
Rufinamide—Anxiety—Epirubicin—bone cancer	0.00028	0.00331	CcSEcCtD
Rufinamide—Skin disorder—Methotrexate—bone cancer	0.000279	0.0033	CcSEcCtD
Rufinamide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	0.000279	0.0033	CcSEcCtD
Rufinamide—SCN9A—Axon guidance—MET—bone cancer	0.000274	0.00192	CbGpPWpGaD
Rufinamide—Vertigo—Doxorubicin—bone cancer	0.000274	0.00324	CcSEcCtD
Rufinamide—Anorexia—Methotrexate—bone cancer	0.000274	0.00324	CcSEcCtD
Rufinamide—Leukopenia—Doxorubicin—bone cancer	0.000273	0.00323	CcSEcCtD
Rufinamide—Infection—Epirubicin—bone cancer	0.000267	0.00316	CcSEcCtD
Rufinamide—CYP2E1—Tryptophan metabolism—MDM2—bone cancer	0.000265	0.00185	CbGpPWpGaD
Rufinamide—SCN11A—Developmental Biology—MET—bone cancer	0.000264	0.00185	CbGpPWpGaD
Rufinamide—SCN11A—Developmental Biology—CDK4—bone cancer	0.000264	0.00185	CbGpPWpGaD
Rufinamide—Convulsion—Doxorubicin—bone cancer	0.000264	0.00313	CcSEcCtD
Rufinamide—Nervous system disorder—Epirubicin—bone cancer	0.000264	0.00312	CcSEcCtD
Rufinamide—Thrombocytopenia—Epirubicin—bone cancer	0.000263	0.00312	CcSEcCtD
Rufinamide—SCN3A—Axon guidance—MET—bone cancer	0.000262	0.00183	CbGpPWpGaD
Rufinamide—Skin disorder—Epirubicin—bone cancer	0.000261	0.00309	CcSEcCtD
Rufinamide—SCN7A—Axon guidance—MMP9—bone cancer	0.000261	0.00182	CbGpPWpGaD
Rufinamide—Insomnia—Methotrexate—bone cancer	0.00026	0.00308	CcSEcCtD
Rufinamide—Anxiety—Doxorubicin—bone cancer	0.000259	0.00306	CcSEcCtD
Rufinamide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	0.000258	0.00305	CcSEcCtD
Rufinamide—Anorexia—Epirubicin—bone cancer	0.000256	0.00303	CcSEcCtD
Rufinamide—Somnolence—Methotrexate—bone cancer	0.000255	0.00302	CcSEcCtD
Rufinamide—Dyspepsia—Methotrexate—bone cancer	0.000253	0.00299	CcSEcCtD
Rufinamide—SCN4A—Axon guidance—MET—bone cancer	0.000252	0.00176	CbGpPWpGaD
Rufinamide—SCN2A—Axon guidance—MET—bone cancer	0.000252	0.00176	CbGpPWpGaD
Rufinamide—Decreased appetite—Methotrexate—bone cancer	0.00025	0.00296	CcSEcCtD
Rufinamide—Gastrointestinal disorder—Methotrexate—bone cancer	0.000248	0.00294	CcSEcCtD
Rufinamide—Fatigue—Methotrexate—bone cancer	0.000248	0.00293	CcSEcCtD
Rufinamide—SCN7A—Developmental Biology—MMP2—bone cancer	0.000248	0.00173	CbGpPWpGaD
Rufinamide—Infection—Doxorubicin—bone cancer	0.000247	0.00293	CcSEcCtD
Rufinamide—Nervous system disorder—Doxorubicin—bone cancer	0.000244	0.00289	CcSEcCtD
Rufinamide—Thrombocytopenia—Doxorubicin—bone cancer	0.000244	0.00288	CcSEcCtD
Rufinamide—Insomnia—Epirubicin—bone cancer	0.000243	0.00288	CcSEcCtD
Rufinamide—SCN1A—Axon guidance—MET—bone cancer	0.000243	0.0017	CbGpPWpGaD
Rufinamide—SCN10A—Axon guidance—MET—bone cancer	0.000243	0.0017	CbGpPWpGaD
Rufinamide—SCN8A—Developmental Biology—MET—bone cancer	0.000242	0.00169	CbGpPWpGaD
Rufinamide—SCN8A—Developmental Biology—CDK4—bone cancer	0.000242	0.00169	CbGpPWpGaD
Rufinamide—Skin disorder—Doxorubicin—bone cancer	0.000242	0.00286	CcSEcCtD
Rufinamide—Somnolence—Epirubicin—bone cancer	0.000239	0.00283	CcSEcCtD
Rufinamide—Anorexia—Doxorubicin—bone cancer	0.000237	0.00281	CcSEcCtD
Rufinamide—Dyspepsia—Epirubicin—bone cancer	0.000237	0.0028	CcSEcCtD
Rufinamide—Decreased appetite—Epirubicin—bone cancer	0.000234	0.00277	CcSEcCtD
Rufinamide—SCN11A—Axon guidance—MMP9—bone cancer	0.000232	0.00162	CbGpPWpGaD
Rufinamide—Gastrointestinal disorder—Epirubicin—bone cancer	0.000232	0.00275	CcSEcCtD
Rufinamide—Fatigue—Epirubicin—bone cancer	0.000232	0.00274	CcSEcCtD
Rufinamide—Constipation—Epirubicin—bone cancer	0.00023	0.00272	CcSEcCtD
Rufinamide—SCN5A—L1CAM interactions—EGFR—bone cancer	0.000229	0.0016	CbGpPWpGaD
Rufinamide—SCN9A—Axon guidance—MMP2—bone cancer	0.000229	0.0016	CbGpPWpGaD
Rufinamide—Insomnia—Doxorubicin—bone cancer	0.000225	0.00266	CcSEcCtD
Rufinamide—Somnolence—Doxorubicin—bone cancer	0.000221	0.00262	CcSEcCtD
Rufinamide—SCN11A—Developmental Biology—MMP2—bone cancer	0.000221	0.00154	CbGpPWpGaD
Rufinamide—Dyspepsia—Doxorubicin—bone cancer	0.000219	0.00259	CcSEcCtD
Rufinamide—SCN3A—Axon guidance—MMP2—bone cancer	0.000219	0.00153	CbGpPWpGaD
Rufinamide—Decreased appetite—Doxorubicin—bone cancer	0.000216	0.00256	CcSEcCtD
Rufinamide—GRM5—Signaling Pathways—SMO—bone cancer	0.000215	0.00151	CbGpPWpGaD
Rufinamide—Gastrointestinal disorder—Doxorubicin—bone cancer	0.000215	0.00254	CcSEcCtD
Rufinamide—Fatigue—Doxorubicin—bone cancer	0.000215	0.00254	CcSEcCtD
Rufinamide—Constipation—Doxorubicin—bone cancer	0.000213	0.00252	CcSEcCtD
Rufinamide—SCN8A—Axon guidance—MMP9—bone cancer	0.000213	0.00149	CbGpPWpGaD
Rufinamide—Hypersensitivity—Methotrexate—bone cancer	0.000212	0.00251	CcSEcCtD
Rufinamide—SCN7A—Axon guidance—EGFR—bone cancer	0.000211	0.00147	CbGpPWpGaD
Rufinamide—SCN2A—Axon guidance—MMP2—bone cancer	0.00021	0.00147	CbGpPWpGaD
Rufinamide—SCN4A—Axon guidance—MMP2—bone cancer	0.00021	0.00147	CbGpPWpGaD
Rufinamide—Asthenia—Methotrexate—bone cancer	0.000206	0.00244	CcSEcCtD
Rufinamide—Pruritus—Methotrexate—bone cancer	0.000203	0.00241	CcSEcCtD
Rufinamide—SCN10A—Axon guidance—MMP2—bone cancer	0.000203	0.00142	CbGpPWpGaD
Rufinamide—SCN1A—Axon guidance—MMP2—bone cancer	0.000203	0.00142	CbGpPWpGaD
Rufinamide—SCN8A—Developmental Biology—MMP2—bone cancer	0.000202	0.00141	CbGpPWpGaD
Rufinamide—CYP2E1—Biological oxidations—CYP3A4—bone cancer	0.000201	0.0014	CbGpPWpGaD
Rufinamide—Hypersensitivity—Epirubicin—bone cancer	0.000198	0.00234	CcSEcCtD
Rufinamide—CYP2E1—Metapathway biotransformation—CYP3A4—bone cancer	0.000198	0.00138	CbGpPWpGaD
Rufinamide—SCN5A—SIDS Susceptibility Pathways—JUN—bone cancer	0.000197	0.00138	CbGpPWpGaD
Rufinamide—GRM5—Signaling Pathways—GNA11—bone cancer	0.000197	0.00138	CbGpPWpGaD
Rufinamide—Diarrhoea—Methotrexate—bone cancer	0.000197	0.00233	CcSEcCtD
Rufinamide—SCN9A—Developmental Biology—CDK4—bone cancer	0.000196	0.00137	CbGpPWpGaD
Rufinamide—SCN9A—Developmental Biology—MET—bone cancer	0.000196	0.00137	CbGpPWpGaD
Rufinamide—Asthenia—Epirubicin—bone cancer	0.000193	0.00228	CcSEcCtD
Rufinamide—Pruritus—Epirubicin—bone cancer	0.00019	0.00225	CcSEcCtD
Rufinamide—Dizziness—Methotrexate—bone cancer	0.00019	0.00225	CcSEcCtD
Rufinamide—SCN11A—Axon guidance—EGFR—bone cancer	0.000188	0.00131	CbGpPWpGaD
Rufinamide—SCN3A—Developmental Biology—MET—bone cancer	0.000187	0.00131	CbGpPWpGaD
Rufinamide—SCN3A—Developmental Biology—CDK4—bone cancer	0.000187	0.00131	CbGpPWpGaD
Rufinamide—SCN7A—Developmental Biology—MMP9—bone cancer	0.000186	0.0013	CbGpPWpGaD
Rufinamide—Diarrhoea—Epirubicin—bone cancer	0.000184	0.00218	CcSEcCtD
Rufinamide—Hypersensitivity—Doxorubicin—bone cancer	0.000183	0.00217	CcSEcCtD
Rufinamide—GRM5—Signaling Pathways—ATF1—bone cancer	0.000183	0.00128	CbGpPWpGaD
Rufinamide—Vomiting—Methotrexate—bone cancer	0.000183	0.00216	CcSEcCtD
Rufinamide—Rash—Methotrexate—bone cancer	0.000181	0.00214	CcSEcCtD
Rufinamide—Dermatitis—Methotrexate—bone cancer	0.000181	0.00214	CcSEcCtD
Rufinamide—Headache—Methotrexate—bone cancer	0.00018	0.00213	CcSEcCtD
Rufinamide—SCN4A—Developmental Biology—MET—bone cancer	0.00018	0.00126	CbGpPWpGaD
Rufinamide—SCN2A—Developmental Biology—MET—bone cancer	0.00018	0.00126	CbGpPWpGaD
Rufinamide—SCN4A—Developmental Biology—CDK4—bone cancer	0.00018	0.00126	CbGpPWpGaD
Rufinamide—SCN2A—Developmental Biology—CDK4—bone cancer	0.00018	0.00126	CbGpPWpGaD
Rufinamide—GRM5—Signaling Pathways—IL3—bone cancer	0.000179	0.00125	CbGpPWpGaD
Rufinamide—Asthenia—Doxorubicin—bone cancer	0.000179	0.00211	CcSEcCtD
Rufinamide—Dizziness—Epirubicin—bone cancer	0.000178	0.0021	CcSEcCtD
Rufinamide—Pruritus—Doxorubicin—bone cancer	0.000176	0.00208	CcSEcCtD
Rufinamide—SCN1A—Developmental Biology—CDK4—bone cancer	0.000173	0.00121	CbGpPWpGaD
Rufinamide—SCN1A—Developmental Biology—MET—bone cancer	0.000173	0.00121	CbGpPWpGaD
Rufinamide—SCN10A—Developmental Biology—MET—bone cancer	0.000173	0.00121	CbGpPWpGaD
Rufinamide—SCN10A—Developmental Biology—CDK4—bone cancer	0.000173	0.00121	CbGpPWpGaD
Rufinamide—SCN9A—Axon guidance—MMP9—bone cancer	0.000172	0.0012	CbGpPWpGaD
Rufinamide—SCN8A—Axon guidance—EGFR—bone cancer	0.000172	0.0012	CbGpPWpGaD
Rufinamide—CYP2E1—Biological oxidations—GSTP1—bone cancer	0.000172	0.0012	CbGpPWpGaD
Rufinamide—Vomiting—Epirubicin—bone cancer	0.000171	0.00202	CcSEcCtD
Rufinamide—SCN5A—Axon guidance—MET—bone cancer	0.000171	0.00119	CbGpPWpGaD
Rufinamide—Nausea—Methotrexate—bone cancer	0.000171	0.00202	CcSEcCtD
Rufinamide—Diarrhoea—Doxorubicin—bone cancer	0.00017	0.00201	CcSEcCtD
Rufinamide—ALB—Platelet activation, signaling and aggregation—SPARC—bone cancer	0.00017	0.00119	CbGpPWpGaD
Rufinamide—Rash—Epirubicin—bone cancer	0.00017	0.00201	CcSEcCtD
Rufinamide—Dermatitis—Epirubicin—bone cancer	0.000169	0.002	CcSEcCtD
Rufinamide—CYP2E1—Metapathway biotransformation—GSTP1—bone cancer	0.000169	0.00118	CbGpPWpGaD
Rufinamide—Headache—Epirubicin—bone cancer	0.000168	0.00199	CcSEcCtD
Rufinamide—SCN11A—Developmental Biology—MMP9—bone cancer	0.000166	0.00116	CbGpPWpGaD
Rufinamide—Dizziness—Doxorubicin—bone cancer	0.000165	0.00195	CcSEcCtD
Rufinamide—SCN3A—Axon guidance—MMP9—bone cancer	0.000164	0.00115	CbGpPWpGaD
Rufinamide—SCN9A—Developmental Biology—MMP2—bone cancer	0.000163	0.00114	CbGpPWpGaD
Rufinamide—Nausea—Epirubicin—bone cancer	0.00016	0.00189	CcSEcCtD
Rufinamide—Vomiting—Doxorubicin—bone cancer	0.000158	0.00187	CcSEcCtD
Rufinamide—SCN2A—Axon guidance—MMP9—bone cancer	0.000158	0.0011	CbGpPWpGaD
Rufinamide—SCN4A—Axon guidance—MMP9—bone cancer	0.000158	0.0011	CbGpPWpGaD
Rufinamide—Rash—Doxorubicin—bone cancer	0.000157	0.00186	CcSEcCtD
Rufinamide—Dermatitis—Doxorubicin—bone cancer	0.000157	0.00185	CcSEcCtD
Rufinamide—SCN3A—Developmental Biology—MMP2—bone cancer	0.000156	0.00109	CbGpPWpGaD
Rufinamide—Headache—Doxorubicin—bone cancer	0.000156	0.00184	CcSEcCtD
Rufinamide—ALB—Platelet activation, signaling and aggregation—GNA11—bone cancer	0.000156	0.00109	CbGpPWpGaD
Rufinamide—GRM5—Signaling Pathways—TGFBR2—bone cancer	0.000153	0.00107	CbGpPWpGaD
Rufinamide—SCN10A—Axon guidance—MMP9—bone cancer	0.000152	0.00106	CbGpPWpGaD
Rufinamide—SCN1A—Axon guidance—MMP9—bone cancer	0.000152	0.00106	CbGpPWpGaD
Rufinamide—SCN8A—Developmental Biology—MMP9—bone cancer	0.000152	0.00106	CbGpPWpGaD
Rufinamide—SCN7A—Developmental Biology—EGFR—bone cancer	0.00015	0.00105	CbGpPWpGaD
Rufinamide—SCN4A—Developmental Biology—MMP2—bone cancer	0.00015	0.00105	CbGpPWpGaD
Rufinamide—SCN2A—Developmental Biology—MMP2—bone cancer	0.00015	0.00105	CbGpPWpGaD
Rufinamide—Nausea—Doxorubicin—bone cancer	0.000148	0.00175	CcSEcCtD
Rufinamide—SCN10A—Developmental Biology—MMP2—bone cancer	0.000145	0.00101	CbGpPWpGaD
Rufinamide—SCN1A—Developmental Biology—MMP2—bone cancer	0.000145	0.00101	CbGpPWpGaD
Rufinamide—GRM5—Signaling Pathways—IGF1R—bone cancer	0.000144	0.001	CbGpPWpGaD
Rufinamide—SCN5A—Axon guidance—MMP2—bone cancer	0.000142	0.000996	CbGpPWpGaD
Rufinamide—ALB—Platelet activation, signaling and aggregation—IL3—bone cancer	0.000141	0.000986	CbGpPWpGaD
Rufinamide—SCN9A—Axon guidance—EGFR—bone cancer	0.000139	0.000971	CbGpPWpGaD
Rufinamide—SCN11A—Developmental Biology—EGFR—bone cancer	0.000134	0.000936	CbGpPWpGaD
Rufinamide—SCN3A—Axon guidance—EGFR—bone cancer	0.000133	0.000928	CbGpPWpGaD
Rufinamide—ALB—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000132	0.000924	CbGpPWpGaD
Rufinamide—ALB—Selenium Micronutrient Network—PTGS2—bone cancer	0.000131	0.000913	CbGpPWpGaD
Rufinamide—SCN4A—Axon guidance—EGFR—bone cancer	0.000128	0.000892	CbGpPWpGaD
Rufinamide—SCN2A—Axon guidance—EGFR—bone cancer	0.000128	0.000892	CbGpPWpGaD
Rufinamide—SCN1A—Axon guidance—EGFR—bone cancer	0.000123	0.00086	CbGpPWpGaD
Rufinamide—SCN10A—Axon guidance—EGFR—bone cancer	0.000123	0.00086	CbGpPWpGaD
Rufinamide—CYP3A4—Tryptophan metabolism—MDM2—bone cancer	0.000123	0.000859	CbGpPWpGaD
Rufinamide—SCN9A—Developmental Biology—MMP9—bone cancer	0.000123	0.000857	CbGpPWpGaD
Rufinamide—SCN8A—Developmental Biology—EGFR—bone cancer	0.000123	0.000856	CbGpPWpGaD
Rufinamide—SCN5A—Developmental Biology—MET—bone cancer	0.000122	0.000852	CbGpPWpGaD
Rufinamide—SCN5A—Developmental Biology—CDK4—bone cancer	0.000122	0.000852	CbGpPWpGaD
Rufinamide—CYP2E1—Metabolism—NDUFA12—bone cancer	0.00012	0.00084	CbGpPWpGaD
Rufinamide—SCN3A—Developmental Biology—MMP9—bone cancer	0.000117	0.00082	CbGpPWpGaD
Rufinamide—ALB—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000114	0.000798	CbGpPWpGaD
Rufinamide—SCN4A—Developmental Biology—MMP9—bone cancer	0.000113	0.000788	CbGpPWpGaD
Rufinamide—SCN2A—Developmental Biology—MMP9—bone cancer	0.000113	0.000788	CbGpPWpGaD
Rufinamide—SCN1A—Developmental Biology—MMP9—bone cancer	0.000109	0.00076	CbGpPWpGaD
Rufinamide—SCN10A—Developmental Biology—MMP9—bone cancer	0.000109	0.00076	CbGpPWpGaD
Rufinamide—SCN5A—Axon guidance—MMP9—bone cancer	0.000107	0.000748	CbGpPWpGaD
Rufinamide—GRM5—Signaling Pathways—KIT—bone cancer	0.000104	0.000728	CbGpPWpGaD
Rufinamide—ALB—Metabolism—NDUFA12—bone cancer	0.000103	0.000722	CbGpPWpGaD
Rufinamide—SCN5A—Developmental Biology—MMP2—bone cancer	0.000102	0.00071	CbGpPWpGaD
Rufinamide—CYP2E1—Metabolism—NT5C3A—bone cancer	9.96e-05	0.000696	CbGpPWpGaD
Rufinamide—SCN9A—Developmental Biology—EGFR—bone cancer	9.91e-05	0.000693	CbGpPWpGaD
Rufinamide—GRM5—Signaling Pathways—BRAF—bone cancer	9.8e-05	0.000685	CbGpPWpGaD
Rufinamide—ALB—Folate Metabolism—TP53—bone cancer	9.78e-05	0.000684	CbGpPWpGaD
Rufinamide—GRM5—Signaling by GPCR—EGFR—bone cancer	9.5e-05	0.000664	CbGpPWpGaD
Rufinamide—SCN3A—Developmental Biology—EGFR—bone cancer	9.48e-05	0.000662	CbGpPWpGaD
Rufinamide—SCN4A—Developmental Biology—EGFR—bone cancer	9.11e-05	0.000636	CbGpPWpGaD
Rufinamide—SCN2A—Developmental Biology—EGFR—bone cancer	9.11e-05	0.000636	CbGpPWpGaD
Rufinamide—SCN10A—Developmental Biology—EGFR—bone cancer	8.78e-05	0.000614	CbGpPWpGaD
Rufinamide—SCN1A—Developmental Biology—EGFR—bone cancer	8.78e-05	0.000614	CbGpPWpGaD
Rufinamide—ALB—Hemostasis—SPARC—bone cancer	8.77e-05	0.000613	CbGpPWpGaD
Rufinamide—SCN5A—Axon guidance—EGFR—bone cancer	8.65e-05	0.000605	CbGpPWpGaD
Rufinamide—ALB—Metabolism—NT5C3A—bone cancer	8.56e-05	0.000599	CbGpPWpGaD
Rufinamide—GRM5—Signaling Pathways—MDM2—bone cancer	8.21e-05	0.000574	CbGpPWpGaD
Rufinamide—ALB—Hemostasis—GNA11—bone cancer	8.02e-05	0.000561	CbGpPWpGaD
Rufinamide—CYP3A4—Biological oxidations—GSTP1—bone cancer	7.96e-05	0.000556	CbGpPWpGaD
Rufinamide—CYP3A4—Metapathway biotransformation—GSTP1—bone cancer	7.85e-05	0.000549	CbGpPWpGaD
Rufinamide—SCN5A—Developmental Biology—MMP9—bone cancer	7.64e-05	0.000534	CbGpPWpGaD
Rufinamide—ALB—Hemostasis—IL3—bone cancer	7.27e-05	0.000508	CbGpPWpGaD
Rufinamide—GRM5—Signaling Pathways—JUN—bone cancer	7.13e-05	0.000499	CbGpPWpGaD
Rufinamide—GRM5—Signaling Pathways—MMP9—bone cancer	6.94e-05	0.000485	CbGpPWpGaD
Rufinamide—SCN5A—Developmental Biology—EGFR—bone cancer	6.17e-05	0.000431	CbGpPWpGaD
Rufinamide—GRM5—Signaling Pathways—EGFR—bone cancer	5.61e-05	0.000392	CbGpPWpGaD
Rufinamide—CYP3A4—Metabolism—NDUFA12—bone cancer	5.58e-05	0.00039	CbGpPWpGaD
Rufinamide—ALB—Hemostasis—PLAU—bone cancer	4.77e-05	0.000333	CbGpPWpGaD
Rufinamide—GRM5—Signaling Pathways—TP53—bone cancer	4.71e-05	0.000329	CbGpPWpGaD
Rufinamide—CYP3A4—Metabolism—NT5C3A—bone cancer	4.62e-05	0.000323	CbGpPWpGaD
Rufinamide—CYP2E1—Metabolism—ENO2—bone cancer	4.36e-05	0.000305	CbGpPWpGaD
Rufinamide—CYP2E1—Metabolism—DHFR—bone cancer	4.05e-05	0.000283	CbGpPWpGaD
Rufinamide—CYP2E1—Metabolism—GNA11—bone cancer	3.78e-05	0.000264	CbGpPWpGaD
Rufinamide—ALB—Metabolism—ENO2—bone cancer	3.75e-05	0.000262	CbGpPWpGaD
Rufinamide—ALB—Metabolism—DHFR—bone cancer	3.48e-05	0.000243	CbGpPWpGaD
Rufinamide—CYP2E1—Metabolism—CYP3A4—bone cancer	3.43e-05	0.00024	CbGpPWpGaD
Rufinamide—ALB—Metabolism—GNA11—bone cancer	3.25e-05	0.000227	CbGpPWpGaD
Rufinamide—ALB—Metabolism—CYP3A4—bone cancer	2.95e-05	0.000206	CbGpPWpGaD
Rufinamide—CYP2E1—Metabolism—GSTP1—bone cancer	2.93e-05	0.000205	CbGpPWpGaD
Rufinamide—ALB—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	2.93e-05	0.000205	CbGpPWpGaD
Rufinamide—ALB—Metabolism—GSTP1—bone cancer	2.52e-05	0.000176	CbGpPWpGaD
Rufinamide—CYP3A4—Metabolism—ENO2—bone cancer	2.03e-05	0.000142	CbGpPWpGaD
Rufinamide—ALB—Hemostasis—TP53—bone cancer	1.92e-05	0.000134	CbGpPWpGaD
Rufinamide—CYP3A4—Metabolism—DHFR—bone cancer	1.88e-05	0.000131	CbGpPWpGaD
Rufinamide—CYP3A4—Metabolism—GNA11—bone cancer	1.76e-05	0.000123	CbGpPWpGaD
Rufinamide—CYP2E1—Metabolism—PTGS2—bone cancer	1.52e-05	0.000106	CbGpPWpGaD
Rufinamide—CYP3A4—Metabolism—GSTP1—bone cancer	1.36e-05	9.51e-05	CbGpPWpGaD
Rufinamide—ALB—Metabolism—PTGS2—bone cancer	1.31e-05	9.13e-05	CbGpPWpGaD
Rufinamide—CYP3A4—Metabolism—PTGS2—bone cancer	7.05e-06	4.93e-05	CbGpPWpGaD
